CA3055204A1 - Compositions et procedes pour induire des anticorps anti-vih-1 - Google Patents

Compositions et procedes pour induire des anticorps anti-vih-1 Download PDF

Info

Publication number
CA3055204A1
CA3055204A1 CA3055204A CA3055204A CA3055204A1 CA 3055204 A1 CA3055204 A1 CA 3055204A1 CA 3055204 A CA3055204 A CA 3055204A CA 3055204 A CA3055204 A CA 3055204A CA 3055204 A1 CA3055204 A1 CA 3055204A1
Authority
CA
Canada
Prior art keywords
envelope
hiv
antibodies
trimer
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3055204A
Other languages
English (en)
Inventor
Barton F. Haynes
Kevin O. Saunders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/020823 external-priority patent/WO2017152146A2/fr
Application filed by Duke University filed Critical Duke University
Publication of CA3055204A1 publication Critical patent/CA3055204A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Selon certains aspects, l'invention concerne des immunogènes du VIH-1, comprenant des enveloppes (CH0848) et des sélections de ces dernières, et des procédés d'immunisation en essaim à l'aide de combinaisons d'enveloppes de VIH-1.
CA3055204A 2017-03-03 2018-03-02 Compositions et procedes pour induire des anticorps anti-vih-1 Pending CA3055204A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2017/020823 WO2017152146A2 (fr) 2016-03-03 2017-03-03 Compositions et procédés pour induire des anticorps du vih-1
USPCT/US2017/020823 2017-03-03
US201862624620P 2018-01-31 2018-01-31
US62/624,620 2018-01-31
PCT/US2018/020788 WO2018161049A1 (fr) 2017-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1

Publications (1)

Publication Number Publication Date
CA3055204A1 true CA3055204A1 (fr) 2018-09-07

Family

ID=63371208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055204A Pending CA3055204A1 (fr) 2017-03-03 2018-03-02 Compositions et procedes pour induire des anticorps anti-vih-1

Country Status (3)

Country Link
EP (1) EP3589315A4 (fr)
CA (1) CA3055204A1 (fr)
WO (1) WO2018161049A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884704B2 (en) 2016-03-01 2024-01-30 Duke University Compositions comprising HIV envelopes to induce CH235 lineage antibodies

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (fr) 2016-10-03 2020-07-08 Duke University Procédés d'identification d'immunogènes par ciblage de mutations improbables
US20210009640A1 (en) * 2018-03-02 2021-01-14 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
EP3860637A4 (fr) * 2018-10-01 2022-08-17 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
JP7483234B2 (ja) * 2018-12-04 2024-05-15 ザ ロックフェラー ユニバーシティー Ｈｉｖワクチン免疫原
US20230382952A1 (en) * 2020-10-19 2023-11-30 Bette T. Korber Compositions comprising hiv envelopes to induce hiv-1 antibodies
CA3206343A1 (fr) * 2021-01-28 2022-08-04 Rory HENDERSON Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
WO2022192262A1 (fr) * 2021-03-08 2022-09-15 Duke University Nanoparticules de glycopeptides de l'enveloppe du vih-1 et leurs utilisations
WO2023064280A2 (fr) * 2021-10-11 2023-04-20 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
WO2025245259A2 (fr) * 2024-05-21 2025-11-27 Dana-Farber Cancer Institute, Inc. Compositions immunogènes dirigées contre le vih-1 et leurs méthodes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (fr) * 2012-09-12 2014-03-20 Duke University Anticorps du lignage clonal
WO2015127108A1 (fr) 2014-02-19 2015-08-27 Duke University Enveloppes du vih -1 trimères des compositions et leurs utilisations
US10322141B2 (en) * 2014-03-31 2019-06-18 Duke University Compositions comprising CH848 envelopes and uses thereof
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884704B2 (en) 2016-03-01 2024-01-30 Duke University Compositions comprising HIV envelopes to induce CH235 lineage antibodies

Also Published As

Publication number Publication date
EP3589315A1 (fr) 2020-01-08
WO2018161049A8 (fr) 2018-10-04
EP3589315A4 (fr) 2021-06-23
WO2018161049A1 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
US11246920B2 (en) Compositions and methods for inducing HIV-1 antibodies
CA3055204A1 (fr) Compositions et procedes pour induire des anticorps anti-vih-1
US11318197B2 (en) Compositions and methods for inducing HIV-1 antibodies
US11884704B2 (en) Compositions comprising HIV envelopes to induce CH235 lineage antibodies
US11746143B2 (en) Methods to identify immunogens by targeting improbable mutations
Williams et al. Identification of HIV gp41-specific antibodies that mediate killing of infected cells
US11814413B2 (en) Compositions comprising modified HIV envelopes
Krebs et al. Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA
US10005819B2 (en) Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
Zhu et al. Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies
CA3039089C (fr) Procedes d'identification d'immunogenes par ciblage de mutations improbables
CA3064345C (fr) Compositions comprenant des enveloppes de vih modifiees
Cheng Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)
Harley Production and characterization of novel immunogens and their applications in pioneering vaccination strategies for induction of broadly neutralizing antibodies against HIV-1
Regula Fusion glycoproteins of HIV-1 and the Ebola Virus: Structure, function, and inhibition with antibodies
Gray Characterization of Neutralizing Antibody Epitopes on HIV-1 Subtype C Envelope Glycoproteins to Support Vaccine Design
Essomba Genetic and immunological characterization of new subtype G envelope expressing HIV-1 pseudoviruses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250107

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250618

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260220

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260223